Search by Drug Name or NDC
NDC 71288-0713-21 Cisatracurium Besylate 200 mg/20mL Details
Cisatracurium Besylate 200 mg/20mL
Cisatracurium Besylate is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Meitheal Pharmaceuticals Inc.. The primary component is CISATRACURIUM BESYLATE.
Product Information
| NDC | 71288-0713 |
|---|---|
| Product ID | 71288-713_d3c597b7-517b-4d79-9fdd-fa88f920111a |
| Associated GPIs | 74200013102035 |
| GCN Sequence Number | 024613 |
| GCN Sequence Number Description | cisatracurium besylate VIAL 10 MG/ML INTRAVEN |
| HIC3 | S7A |
| HIC3 Description | NEUROMUSCULAR BLOCKING AGENTS |
| GCN | 32770 |
| HICL Sequence Number | 010278 |
| HICL Sequence Number Description | CISATRACURIUM BESYLATE |
| Brand/Generic | Generic |
| Proprietary Name | Cisatracurium Besylate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Cisatracurium Besylate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/20mL |
| Substance Name | CISATRACURIUM BESYLATE |
| Labeler Name | Meitheal Pharmaceuticals Inc. |
| Pharmaceutical Class | Neuromuscular Nondepolarizing Blockade [PE], Nondepolarizing Neuromuscular Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA211668 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 71288-0713-21 (71288071321)
| NDC Package Code | 71288-713-21 |
|---|---|
| Billing NDC | 71288071321 |
| Package | 10 VIAL, SINGLE-DOSE in 1 CARTON (71288-713-21) / 20 mL in 1 VIAL, SINGLE-DOSE (71288-713-20) |
| Marketing Start Date | 2019-10-31 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |